650628-09-4

Basic information

• Product Name: 4H-Pyrazolo[3,4-d]pyrimidin-4-one, 1,5-dihydro-1-(3-methylphenyl)-
• Synonyms: 4H-Pyrazolo[3,4-d]pyrimidin-4-one, 1,5-dihydro-1-(3-methylphenyl)-;1-(m-tolyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ol;1-m-Tolyl-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one
• CAS NO: 650628-09-4
• Molecular Formula: C₁₂H₁₀N₄O
• Molecular Weight: 226.24
• Mol File: 650628-09-4.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4H-Pyrazolo[3,4-d]pyrimidin-4-one, 1,5-dihydro-1-(3-methylphenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 4H-Pyrazolo[3,4-d]pyrimidin-4-one, 1,5-dihydro-1-(3-methylphenyl)-(650628-09-4)
• EPA Substance Registry System: 4H-Pyrazolo[3,4-d]pyrimidin-4-one, 1,5-dihydro-1-(3-methylphenyl)-(650628-09-4)

Safety Data

• Hazardous Substances Data: 650628-09-4(Hazardous Substances Data)

Usage

Core Structure

Pyrazolo[3,4-d]pyrimidin-4-one

Substituent

1,5-dihydro-1-(3-methylphenyl)

Pharmaceutical Potential

Due to its ability to bind to specific receptors, it's a candidate for drug development

Interest in Medicinal Chemistry

Researchers are intrigued by its structure and properties for medicinal chemistry and drug discovery

Upstream product

• 536-89-0 m-tolylhydrazine 

Downstream Products

• 650628-11-8 4-chloro-1-(3-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidine 
• 650628-07-2 4-hydrazino-1-(3-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidine 

Relevant articles and documents

PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS

The invention relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula: where m, n, X1, X2, R1-R5, R5′ and R6 are described herein.

Identification of novel GLUT inhibitors

The compound class of 1H-pyrazolo[3,4-d]pyrimidines was identified using HTS as very potent inhibitors of facilitated glucose transporter 1 (GLUT1). Extensive structure–activity relationship studies (SAR) of each ring system of the molecular framework was established revealing essential structural motives (i.e., ortho-methoxy substituted benzene, piperazine and pyrimidine). The selectivity against GLUT2 was excellent and initial in vitro and in vivo pharmacokinetic (PK) studies are encouraging.

NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI-CANCER AGENTS

The invention relates to substituted pyrazolo[3,4-d]pyrimidine derivatives of the Formula-(I), or pharmaceutically acceptable salts thereof, which possess anti-proliferative activity such as anti-cancer activity and are accordingly useful in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of substituted pyrazolo[3,4-d]pyrimidine derivatives, to pharmaceutical compositions containing the compound and to its use in the manufacture of medicaments for the production of an anti-proliferative effect in a warm-blooded animal such as man

Novel pyrazolopyrimidine derivatives as GSK-3 inhibitors

A series of [1-aryl-1H-pyrazolo[3,4-d]pyrimidin-4-yl]arylhydrazones were discovered as novel inhibitors glycogen synthase kinase-3 (GSK-3). Based on initial modeling a detailed SAR was constructed. Modification of the interior binding aryl ring (Ar1) determined this to be a tight binding region with little room for modification. As predicted from the model, a large variety of modifications could be incorporated into the hydrazone aryl ring. This work led to GSK-3 inhibitors in the low nano-molar range.